Surmodics INC Form 4 insider transactions

Surmodics SVP Charles W. Olson reported the conversion of his common stock and stock options into cash following the company's merger into a wholly-owned subsidiary of BCE Parent, LLC.

Surmodics Inc. VP Finance, Corp. Controller John D. Manders reported the conversion of his common stock, RSUs, and stock options into cash following the company's acquisition by BCE Parent, LLC.

Gordon S. Weber, Surmodics' Sr. VP of Legal, GC and Sec., disposed of all common stock and options following the company's merger into BCE Parent, LLC.

Surmodics Inc.'s SVP, Teri Woodwick Sides, reported the disposition of all common stock and conversion of equity awards to cash following the company's merger into BCE Parent, LLC at $43.00 per share.

Surmodics Director David Dantzker disposed of all common stock and stock options following the company's merger into a wholly-owned subsidiary.

A director of Surmodics Inc. reported the disposition of all common stock and derivative securities following the company's merger into a wholly-owned subsidiary of BCE Parent, LLC.

Susan E. Knight, a director of Surmodics Inc., no longer holds common stock or derivative securities following the company's merger into a wholly-owned subsidiary of BCE Parent, LLC.

Surmodics Director Jose H. Bedoya disposed of all common stock and derivative securities following the company's merger into BCE Parent, LLC for $43.00 per share.

Surmodics Chief Financial Officer Timothy J. Arens reported the disposition of all common stock and conversion of stock options into cash following the company's merger into a wholly-owned subsidiary of BCE Parent, LLC.

Joseph J. Stich, SVP of HR and President IVD at Surmodics Inc., reported the disposition of all common stock and derivative securities following the company's merger with BCE Parent, LLC.

Surmodics Inc. CEO Gary R. Maharaj reports the disposition of all common stock and derivative securities following the company's merger into a wholly-owned subsidiary of BCE Parent, LLC.

Director Lisa Wipperman Heine reports exercising stock options and selling shares of Surmodics Inc. on February 18, 2025.

Director David Dantzker reports stock transactions including option exercises and share disposals at Surmodics Inc.

Director Jose H. Bedoya reports the acquisition and disposal of Surmodics Inc. common stock on February 14, 2025.

Surmodics director Susan E. Knight exercised stock options and sold shares on January 24, 2025.

Surmodics' Chief Financial Officer, Timothy J. Arens, sold 1,265 shares of common stock to cover tax obligations.

Surmodics CEO Gary Maharaj sold 4,248 shares of common stock to cover tax obligations related to vesting of shares.

Gordon S. Weber, a Senior Vice President at Surmodics Inc., sold 668 shares of common stock to cover tax obligations.

Teri Woodwick Sides, SVP at Surmodics, disposed of 946 shares of common stock to cover tax obligations.

John D. Manders, VP Finance and Corporate Controller at Surmodics Inc., sold 152 shares of common stock to cover tax obligations.

A Surmodics executive, Joseph J. Stich, sold 1,034 shares of common stock to cover tax obligations.

Surmodics Inc. SVP, Medical Device Coatings, Charles W. Olson, reports the disposal of 959 shares of common stock to cover tax obligations.

Surmodics' Chief Financial Officer, Timothy J. Arens, sold 1,786 shares of common stock to cover tax obligations.

A Surmodics executive sold 1,030 shares of common stock to cover tax obligations related to stock awards.

Surmodics Inc. SVP, Medical Device Coatings, Charles W. Olson, reports the disposal of 1,534 shares of common stock to cover tax obligations.

Surmodics CEO Gary Maharaj sold 6,470 shares of common stock to cover tax obligations related to stock awards.

John Manders, VP Finance and Corporate Controller at Surmodics Inc., reported the disposal of 387 shares of common stock to cover tax obligations.

Surmodics SVP of HR, Joseph J. Stich, disposed of 1,655 shares of common stock to cover tax obligations.

Teri Woodwick Sides, SVP at Surmodics, disposed of 1,312 shares of common stock to cover tax obligations.

Surmodics' Chief Financial Officer, Timothy J. Arens, sold 7,009 shares of common stock on November 26, 2024, at an average price of $39.4426 per share.